Group items tagged

In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to rezafungin from Cidara Therapeutics. This solidified Mundipharma's dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over the 15 years has seen no new therapeutic developments underscoring for alternative options. The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis in adults. While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States. Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

Many of us drink alcohol on a regular basis, and when it comes to the weekend many of us have been known to overindulge a little. For the most part we understand the dangers of alcohol. We have an understanding that it can damage our liver, exacerbate mental health conditions and lead to addiction, with private alcohol treatment one of the few pathways to recovery. However, there are also many other effects that we may not be quite as familiar with, but it is important to know about them, particularly if you are a heavy drinker. Among some of the more common effects you may not be aware of, include… Disruption of REM Sleep Often we think alcohol gives us a better night's sleep, knocking us out for the count. However, while it does aid falling asleep, the quality of that sleep is significantly harmed. It disrupts the normal sleep cycle by reducing the time spent in rapid eye movement sleep, a stage that is important for memory consolidation and cognitive function. This sleep is less restorative and is why we often feel groggy and tired the following day.

A final review of gender services provided by the NHS has uncovered significant shortcomings, leaving thousands of vulnerable children questioning their gender identity without adequate support. The report, led by Dr. Hilary Cass, a prominent consultant paediatrician, highlights the use of unproven treatments and the detrimental impact of the polarized trans debate on gender care provision. The investigation, commissioned by NHS England in 2020, focused on the Tavistock and Portman NHS mental health trust's gender identity development services (Gids), which treated around 9,000 children and young people between 2009 and 2020. Shockingly, the review found that despite limited evidence of effectiveness and potential health risks, puberty blockers and cross-sex hormones were routinely administered. Dr. Cass emphasized that the "rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown."

The incredible consequences that drug misuse has imposed on humans in the last few years make it one of the most pressing issues facing such nations. A person who is addicted to drugs or alcohol often turns to these substances as a crutch while they're going through tough times. Taking the drug regularly becomes habitual since it provides short-term relief without permanently resolving the issue. An important part of becoming sober is learning to substitute better routines for the addict's old, harmful ones. These self-care routines and healthy habits are much better ways to deal with stress. Here we will explain how healthy behavior throughout addiction recovery is simply one of many methods to adapt to life after treatment. Physical Activity Scientific studies have shown that physical activity increases levels of two hormones. dopamine and serotonin, which are linked to better mood. A more positive outlook, restful sleep, and enhanced general health are all possible outcomes of these hormones. In the early stages of your rehabilitation, it is wise to start an exercise regimen that you have never done before. You may find new sober friends and interactions, as well as inspiration to improve your physical health, by connecting with other people who share your interests in physical activity. In the early stages of recovery, having sober friends may be really helpful since it allows you to connect with those who understand what you're going through. Friendships formed in early recovery often continue long after the addict has left the program, according to many people in recovery.

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Kailash Deepak Hospital is Delhi's premier heart healthcare institution, renowned for its top-notch cardiology services. Our distinguished cardiologists and advanced facilities ensure unmatched care for your heart. Experience compassionate and comprehensive treatment at the best heart hospital in Delhi. Your heart's well-being is our commitment.

LloydsPharmacy Clinical Homecare, a leading provider of home healthcare services in the UK, on Monday announced the appointment of Paul Adams as the company's new Chief Executive Officer (CEO). Before assuming his role at LPCH at the end of last year, Adams was leading transformation efforts at DD Group, formerly known as Dental Directory. With a career spanning over two decades, Adams has held influential positions at Diageo, Smith+Nephew, and served as a CEO for various Private Equity companies. He has also co-authored "The Little Black Book of Change." Adams will lead the LPCH's mission to pioneer the delivery of specialist clinical treatment therapies to patients, thereby enhancing patient outcomes within homecare and community settings while improving accessibility.

Veoza, a non-hormonal treatment for menopause, has been made available on the high street for the first time in the UK. British pharmacy chain Superdrug on Thursday (1st February) announced the launch of the newly approved menopause medication, expanding its comprehensive portfolio of products and services to support menopausal women. Veoza is a prescription medication that is used to manage vasomotor symptoms, specifically hot flushes and night sweats, which affect up to 80 per cent of women during menopause, as estimated by experts. It is recommended for women who prefer not to or are unable to take hormone replacement. Perimenopausal, menopausal and postmenopausal women, aged 45-65 who are not on Hormone Replacement Therapy (HRT) or hormonal contraception, and are suffering from moderate to severe vasomotor symptoms, are eligible to take the medication, the retailer said in a release.

The government's 200 million dental recovery plan has come under fierce criticism from the opposition party after health minister Dame Andrea Leadsom admitted that there is a "high likelihood" that it will not deliver 2.5 million dental appointments. Published last month, the plan is aimed at ensuring easier and faster access to NHS dental care across England, with up to 1.5 million extra treatments expected to be delivered over the next 12 months. Various new measures were set out to attract new dentists, including increasing dental training places by up to 40 per cent by 2032, as part of the NHS Long Term Workforce Plan. On Tuesday, Leadsom told MPs on the Health and Social Care Committee that the figure was based on NHS modelling of a "complicated set of factors" and there is "quite a high likelihood of not being reliable as is the case with all modelling." Preeti Kaur Gill MP, shadow minister for primary care and public health, expressed shock over the admission by the public health minister that there is uncertainty regarding the plan's ability to deliver on its promises, which she said: "shows the Conservatives are out of ideas and out of time."

Poverty not only takes a significant toll on people's health but also leads to additional costs for the National Health Service (NHS). Rise in deep poverty, cost-of-living crisis, and high pressure on NHS services have worsened the situation, according to a study published by The King's Fund this week. The report underscored that poverty and deprivation contribute to a greater prevalence of diseases, difficulties in accessing health care, late or delayed treatment, and worse health outcomes. These challenges could be seen across various NHS services, spanning from emergency care to dental services Additionally, it revealed that 30 per cent of people living in the most deprived areas have turned to 999, 111, A&E or a walk-in centre because they could not access a GP appointment. In 2016, the Joseph Rowntree Foundation (JRF) estimated the cost of poverty on health care at £29 billion (£34 billion in current prices). As the proportion of people living in deep poverty has risen, the situation has worsened. In 2021/22, six million people were living in very deep poverty, up from 4.5 million two decades ago. Currently, more than one in five people in the UK are estimated to be living in poverty, the report noted. Deprivation is linked to a range of diet-related health problems, including cardiovascular disease and diabetes, as well as mental illness. According to the report, the depression rate is two times higher among people living in the most deprived areas, compared to the least deprived areas.

Despite the pervasive nature of pain, affecting 93% of the global population annually and leaving one in three individuals in daily discomfort, there exists a concerning reluctance to address and manage pain effectively. This leads to a heightened burden of suffering among people worldwide. Join our complimentary 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, address, and alleviate pain in your patients' lives. Delve into topics such as the pharmacist's evolving role, the significance of timely pain treatment, and initiatives like Haleon's #ListenToPain campaign. This webinar is tailored for pharmacists in GB, especially those in community, practice, PCN, and hospital settings. Don't miss this chance to enhance patient care and contribute positively to pain management. Register now to reserve your spot!

Despite the widespread prevalence of pain, which affects 93% of the global population annually and leaves one in three individuals experiencing daily discomfort, there is a troubling reluctance to effectively address and manage pain. This reluctance contributes to increased suffering among people worldwide. We invite you to join our complimentary 1-hour Pain Management Webinar, thoughtfully designed to provide you and your team with essential strategies for understanding, addressing, and alleviating pain in your patients' lives. Explore topics such as the evolving role of pharmacists, the importance of timely pain treatment, and initiatives like Haleon's #ListenToPain campaign. This webinar is tailored for pharmacists in Great Britain, particularly those working in community, practice, PCN, and hospital settings. Don't miss this opportunity to improve patient care and make a positive impact on pain management. Register now to secure your spot!

Thanks to a new service added to the NHS App, patients in England can now see their prescriptions online and collect their prescribed medication from the nominated pharmacy or a pharmacy of their choice without a paper prescription. NHS England has introduced digital prescriptions in the app following a successful trial last year involving over a million users. Users without a nominated pharmacy can collect their prescriptions from any pharmacy using the barcode in the app, but this is not required for patients with a nominated pharmacy as details would be sent to their pharmacy electronically. From now on, patients waiting for elective hospital treatment can also check the average waiting time for their procedure at their local trust using the NHS App.

The 14th Annual Community Pharmacy Conference by Sigma Pharmaceuticals began on Monday, 25 February at Sun City, South Africa. Dr. Bharat Shah, Manish Shah, and Kamal Shah, co-founders of the company, extended a warm welcome to the delegates in attendance at the event. In a written message, Prime Minister Rishi Sunak extended his best wishes to all the participants attending the conference. The message read: "This conference is timely as it coincides with the launch of the Pharmacy First, a new initiative launched across England that will enable patients to receive treatments for seven common conditions directly from a pharmacist without the need for a GP appointment or prescription." "We are all grateful for the tremendous contributions that pharmacists make to our NHS. The fantastic work you do is critical to the success of Pharmacy First and many other initiatives."

More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC). HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life. Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per year, helping patients save hundreds of pounds in prescription charges. The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months. Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times as needed throughout the year.

In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs. The results of the population-based cohort study were published in Neurology on 7 February 2024. Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between January 2000 and March 2017. None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years. During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the Pharmacy First service, which was launched across England in January 2024. They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment. After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo, shingles, infected insect bites or uncomplicated urinary tract infections in women. The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and Nottingham on the project. Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's impact on GPs and the wider NHS, pharmacy services and patients."

The Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified codeine linctus, a medicine used for the treatment of dry cough, from a pharmacy-only medicine (P) to a prescription-only medicine (POM) owing to the risk of dependence, addiction, and overdose. This implies that the dry cough syrup, which is also known as codeine oral solution, can only be dispensed upon the submission of a prescription at a pharmacy, rather than being accessible over the counter upon request. Patients are cautioned that as an opioid medicine, codeine can be addictive, and the risk of addiction may increase, particularly with prolonged use over an extended period. According to the medicines regulator, codeine is converted into morphine by the liver enzyme CYP2D6. In individuals identified as ultra-rapid metabolizers, this conversion from codeine to morphine occurs at a faster rate than in others. "If you want to stop taking it and have been taking codeine linctus for a long time, then it is important to reduce the amount you take slowly with the help of your prescriber," the agency said in its drug safety update issued on Tuesday, 20 February.